Newsroom | 18682 results

PALO ALTO, Calif.--(BUSINESS WIRE)--Tidepool achieves ISO 13485:2016 certification from accredited certification body TÜV SÜD America for its open-source Quality Management System....

NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today reported that on April 16, 2025, the company granted (i) a non-statutory stock option to purchase 3,300 shares of the company’s common stock to one newly hired employee and (ii) restricted stock units (RSUs) with respect to 12,866 shares of the company’s common stock to six newly hired employees. These grants were made pursuant to the company’s 2021 Inducement Equity Incentive Plan, were approved by the compensation committee of...

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the launch of the Tempus Advisory Board. The Tempus Advisory Board is a vital resource for the company in maintaining high standards and ensuring that the strategy and offerings continue to be grounded in expert knowledge from outside the organization. This group of engaged medical professionals is providing guidance, expertise...

OXFORD, England--(BUSINESS WIRE)--A new paper, released this week on bioRxiv, introduces hifiasm-ONT, a breakthrough genome assembly algorithm that enables partially phased, near telomere-to-telomere (T2T) assemblies1, using Oxford Nanopore Simplex reads and standard sample prep. Developed by Haoyu Cheng, Han Qu, Heng Li, and Peter Park, with support from Oxford Nanopore’s machine learning and applications teams, this major algorithmic innovation unlocks the length advantage of Oxford Nanopore’...

CAIRO--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced new eight-year data showing that patients receiving aortic surgical valves treated with its proprietary RESILIA tissue technology have significantly improved long-term outcomes compared to those receiving non-RESILIA tissue bioprosthetic valves. For more than 65 years, Edwards has been the leader in heart valve innovations. To create a more durable heart valve, Edwards developed the RESILIA tissue technology more than two d...

ABU DHABI, Emirati Arabi Uniti--(BUSINESS WIRE)--Abu Dhabi ha lanciato l'innovativo cluster dedicato al settore delle scienze della vita, rafforzando la sua posizione di hub globale per la biotecnologia, la tecnologia medica e la sanità digitale. Sviluppato dal Dipartimento per lo Sviluppo Economico di Abu Dhabi, dall'Ufficio per gli Investimenti di Abu Dhabi (ADIO) e dal Dipartimento della Salute di Abu Dhabi, il cluster HELM (Health, Endurance, Longevity, and Medicine) è stato progettato per...

ABU DHABI, Verenigde Arabische Emiraten--(BUSINESS WIRE)--Abu Dhabi heeft het baanbrekende life sciences-cluster gelanceerd, waardoor de positie van het land als een wereldwijde hub voor biotechnologie, MedTech en digitale gezondheid wordt versterkt. Het Health, Endurance, Longevity and Medicine (HELM)-cluster is ontwikkeld door het Abu Dhabi Department of Economic Development, Abu Dhabi Investment Office (ADIO) en het Department of Health – Abu Dhabi, en is ontworpen om innovatie in de gezondh...

東京--(BUSINESS WIRE)--(美國商業資訊)-- Rigaku Holdings Corporation旗下子公司Rigaku Corporation（總部：東京昭島市；執行長：Jun Kawakami；以下簡稱「Rigaku」），與SPERA PHARMA, Inc.（總部：大阪市；董事長兼代表董事：Keitaro Iwaki；以下簡稱「SPERA PHARMA」）宣佈達成戰略合作，旨在通過整合雙方尖端技術與深厚專業知識，加速並革新藥物研發進程。 SPERA PHARMA將採用Rigaku提供的電子衍射集成平台XtaLAB Synergy-ED開展合約分析服務，為客戶的藥物研發提供強力支援。 XtaLAB Synergy-ED搭載的3D ED/MicroED1可用於物質結構分析，包括顯微晶體和微量結晶粉末。這項尖端技術具有足夠高的解析度，可以確定原子級結構，從而詳細闡明有機化合物及類似物質的分子結構。 SPERA PHARMA目前是全球醫藥行業唯一一家提供XtaLAB Synergy-ED合約分析服務的企業。Rigaku將為SPERA PHARMA的合約分析業務提供全面...

BILTHOVEN, Holanda y BOSTON--(BUSINESS WIRE)--Avania líder mundial en asesoramiento tecnológico y desarrollo clínico, ha anunciado hoy el nombramiento de Jasmine Saba como vicepresidente ejecutiva de Relaciones estratégicas y de Josh Blacker en el cargo de vicepresidente ejecutivo de Desarrollo del negocio global. Nombran a Saba vicepresidente ejecutiva de Relaciones estratégicas Saba asumirá este nuevo cargo para promover el crecimiento de Avania y para eso se encargará de identificar, estable...

东京--(BUSINESS WIRE)--(美国商业资讯)-- Rigaku Holdings Corporation旗下子公司Rigaku Corporation（总部：东京昭岛市；首席执行官：Jun Kawakami；以下简称“Rigaku”），与SPERA PHARMA, Inc.（总部：大阪市；董事长兼代表董事：Keitaro Iwaki；以下简称“SPERA PHARMA”）宣布达成战略合作，旨在通过整合双方尖端技术与深厚专业知识，加速并革新药物研发进程。 SPERA PHARMA将采用Rigaku提供的电子衍射集成平台XtaLAB Synergy-ED开展合约分析服务，为客户的药物研发提供强力支持。 XtaLAB Synergy-ED搭载的3D ED/MicroED1可用于物质结构分析，包括显微晶体和微量结晶粉末。这项尖端技术具有足够高的分辨率，可以确定原子级结构，实现有机化合物和类似物质分子结构的精密阐明。 SPERA PHARMA目前是全球医药行业唯一一家提供XtaLAB Synergy-ED合约分析服务的企业。Rigaku将为SPERA PHARMA的合约分析业务提供...